Group Gp Lp Column III Acquires 11,893 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 11,893 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was bought at an average cost of $19.89 per share, for a total transaction of $236,551.77. Following the acquisition, the insider owned 1,005,732 shares in the company, valued at approximately $20,004,009.48. The trade was a 1.20% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, January 20th, Group Gp Lp Column III bought 18,052 shares of Surrozen stock. The stock was bought at an average cost of $19.60 per share, for a total transaction of $353,819.20.
• On Friday, January 16th, Group Gp Lp Column III bought 2,562 shares of Surrozen stock. The stock was bought at an average price of $20.00 per share, for a total transaction of $51,240.00.
• On Wednesday, January 14th, Group Gp Lp Column III purchased 5,523 shares of Surrozen stock. The shares were purchased at an average cost of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III purchased 12,470 shares of Surrozen stock. The shares were purchased at an average price of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III acquired 15,100 shares of Surrozen stock. The stock was purchased at an average cost of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III acquired 30,884 shares of Surrozen stock. The stock was purchased at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III bought 5,266 shares of Surrozen stock. The shares were purchased at an average cost of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III bought 315,457 shares of Surrozen stock. The stock was purchased at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Performance

Shares of SRZN opened at $19.17 on Thursday. Surrozen, Inc. has a one year low of $5.90 and a one year high of $24.94. The firm has a market capitalization of $164.29 million, a price-to-earnings ratio of -0.86 and a beta of 0.58. The stock’s fifty day moving average is $19.11 and its 200-day moving average is $14.17.

Surrozen (NASDAQ:SRZN) last released its earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The business had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. Analysts forecast that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Surrozen

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after acquiring an additional 5,702 shares during the period. Stonepine Capital Management LLC increased its holdings in shares of Surrozen by 7.1% during the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares during the period. Stempoint Capital LP raised its position in shares of Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares during the last quarter. Armistice Capital LLC bought a new stake in shares of Surrozen in the second quarter valued at about $536,000. Finally, Braidwell LP acquired a new stake in Surrozen during the second quarter worth about $1,252,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Key Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed several open‑market buys on Jan 6, 13, 14, 15, 16 and 20 totaling tens of thousands of shares (~$641k reported across the most recent three purchases) and now directly owns ~1.02M shares — insider accumulation is often read as a bullish confidence vote. Surrozen (NASDAQ:SRZN) Director Purchases $51,240.00 in Stock
• Positive Sentiment: Major shareholder Group GP LP Column III mirrored the insider purchases (Jan 15, 16 and 20), increasing its stake by ~1.2–1.8% per disclosed tranche to ~1.02M shares — coordinated buying by a large holder reinforces the positive insider signal. Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Acquires 2,562 Shares
• Neutral Sentiment: The disclosures are routine SEC beneficial‑ownership filings that document the trades and updated holdings; they do not indicate corporate actions (e.g., buybacks or financings) by Surrozen itself. SEC filing — Kutzkey purchases
• Negative Sentiment: Company fundamentals remain weak: Surrozen reported a steep Q3 EPS miss (reported -$3.61 vs -$1.17 expected) and minimal revenue, leaving substantial operating losses that could cap the stock’s upside unless clinical or commercial progress materially improves. MarketBeat — SRZN profile

Wall Street Analyst Weigh In

SRZN has been the topic of a number of recent research reports. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.